Cargando…
Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
Emerging evidence has illustrated the importance of epigenomic reprogramming in cancer, with altered post-translational modifications of histones contributing to pathogenesis. However, the contributions of histone modifiers to breast cancer progression are unclear, and how these processes vary betwe...
Autores principales: | Hirukawa, Alison, Smith, Harvey W., Zuo, Dongmei, Dufour, Catherine R., Savage, Paul, Bertos, Nicholas, Johnson, Radia M., Bui, Tung, Bourque, Guillaume, Basik, Mark, Giguère, Vincent, Park, Morag, Muller, William J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6026192/ https://www.ncbi.nlm.nih.gov/pubmed/29959321 http://dx.doi.org/10.1038/s41467-018-04864-8 |
Ejemplares similares
-
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
por: Deblois, Geneviève, et al.
Publicado: (2016) -
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis
por: Smith, Harvey W., et al.
Publicado: (2019) -
Gene-expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes
por: Pepin, François, et al.
Publicado: (2012) -
Verification of EZH2 as a druggable target in metastatic uveal melanoma
por: Jin, Bei, et al.
Publicado: (2020) -
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Sung, Vanessa Y. C., et al.
Publicado: (2021)